enGene Therapeutics (ENGN) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
enGene Therapeutics (ENGN) has outperformed Invivyd (IVVD) over the past year, losing 75.0% versus a loss of 83.5%. Invivyd is the larger company by market cap ($122.0 million vs $116.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | IVVD |
|---|---|---|
| Share price | $1.74 | $0.4127 |
| Market cap | $116.61M | $122.01M |
| 1-day change | -1.14% | -7.45% |
| YTD return | -80.73% | -83.29% |
| 1-year return | -75.00% | -83.49% |
| 5-year return | — | -98.36% |
| EPS (TTM) | $-2.07 | $-0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $53.43M |
| Revenue growth (YoY) | — | +110.47% |
| Net income (latest FY) | $-117.30M | $-52.49M |
| Operating margin | — | -103.99% |
| Net margin | — | -98.25% |
| 52-week high | $12.25 | $3.01 |
| 52-week low | $1.40 | $0.4127 |
| Distance from 52-week high | -85.80% | -86.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +146.55% | +2323.07% |
| Average volume | 1.12M | 5.20M |
| Shares outstanding | 67.02M | 295.63M |
| Employees | 81 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
ENGN vs IVVD FAQ
Which is bigger, enGene Therapeutics or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $122.01M compared with $116.61M for enGene Therapeutics (ENGN).
Which stock has performed better over the past year, ENGN or IVVD?
ENGN returned -75.00% over the past 12 months, compared with -83.49% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.